Skip to content

Study · Randomized controlled trial · n = 73 · 2023

2 results

A randomized controlled trial investigating the effect of liraglutide on self-reported liking and neural responses to food stimuli in participants with obesity.

Coppin G, Muñoz Tord D, Pool ER, Locatelli L, Achaibou A, Erdemli A, León Pérez L, Wuensch L, Cereghetti D, Golay A, Sander D, Pataky Z

International journal of obesity (2005)25 Aug 2023Cited by 14 (Europe PMC)

PMID37626125 (opens in a new tab)PMCIDPMC10663148 (opens in a new tab)DOI10.1038/s41366-023-01370-w (opens in a new tab)PepBankPUB-37626125
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Background/objectivesObesity is a complex condition and the mechanisms involved in weight gain and loss are not fully understood. Liraglutide, a GLP-1 receptor agonist, has been demonstrated to successfully promote weight loss in patients with obesity (OB). Yet, it is unclear whether the observed weight loss is driven by an alteration of food liking. Here we investigated the effects of liraglutide on food liking and the cerebral correlates of liking in OB.Subjects/methodsThis study was a randomized, single-center, double-blind, placebo-controlled, parallel group, prospective clinical trial. 73 participants with OB and without diabetes following a multidisciplinary weight loss program, were randomly assigned (1:1) to receive liraglutide 3.0 mg (37.40 ± 11.18 years old, BMI = 35.89 ± 3.01 kg) or a placebo (40.04 ± 14.10 years old, BMI = 34.88 ± 2.87 kg) subcutaneously once daily for 16 weeks.Interventions/methodsWe investigated liking during food consumption. Participants reported their hedonic experience while consuming a high-calorie food (milkshake) and a tasteless solution. The solutions were administered inside the scanner with a Magnetic Resonance Imaging (MRI)-compatible gustometer to assess neural responses during consumption. The same procedure was repeated during the pre- and post-intervention sessions.ResultsNone of the effects involving the intervention factor reached significance when comparing liking between the pre- and post-intervention sessions or groups. Liking during food reward consumption was associated with the activation of the ventromedial prefrontal cortex (vmPFC) and the amygdala. The liraglutide group lost more weight (BMI post-pre = -3.19 ± 1.28 kg/m2) than the placebo group (BMI post-pre = -0.60 ± 1.26 kg/m2).ConclusionsThese results suggest that liraglutide leads to weight loss without self-report or neural evidence supporting a concomitant reduction of food liking in participants with OB.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide 3.0 mg did not change self-reported food liking between pre- and post-intervention sessions or groups compared with placebo.

    In plain wordsIn adults with obesity, liraglutide did not change how much people liked food, compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSelf-reported food liking
    Study

    n = 73

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    3.0 mg once daily · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    None of the effects involving the intervention factor reached significance when comparing liking between the pre- and post-intervention sessions or groups.
    1 context sentence
    Summary · context
    73 participants with OB and without diabetes following a multidisciplinary weight loss program, were randomly assigned (1:1) to receive liraglutide 3.0 mg (37.40 ± 11.18 years old, BMI = 35.89 ± 3.01 kg) or a placebo (40.04 ± 14.10 years old, BMI = 34.88 ± 2.87 kg) subcutaneously once daily for 16 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, the liraglutide group lost more BMI than the placebo group over 16 weeks.

    In plain wordsIn adults with obesity, people on liraglutide lost more weight than people on placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change
    Study

    n = 73

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg once daily · subcutaneous · 16 weeksAs given in this study (human).

    Measurements

    BMI change
    −3.19 kg/m2
    liraglutide
    BMI change
    −0.6 kg/m2
    placebo

    Source sentences

    Summary
    The liraglutide group lost more weight (BMI post-pre = -3.19 ± 1.28 kg/m2) than the placebo group (BMI post-pre = -0.60 ± 1.26 kg/m2).
    1 context sentence
    Summary · context
    73 participants with OB and without diabetes following a multidisciplinary weight loss program, were randomly assigned (1:1) to receive liraglutide 3.0 mg (37.40 ± 11.18 years old, BMI = 35.89 ± 3.01 kg) or a placebo (40.04 ± 14.10 years old, BMI = 34.88 ± 2.87 kg) subcutaneously once daily for 16 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.